Sandip P. Patel, MD

Future Avenues of Research in Advanced NSCLC

October 20th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss future areas of research and unmet needs in non–small cell lung cancer.

Eye-Catching Data From the 2025 World Conference on Lung Cancer

October 20th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss key data from the 2025 World Conference on Lung Cancer.

Navigating Immunotherapy in Advanced NSCLC After Early-Stage IO Therapy

October 13th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the use of immunotherapy after prior immunotherapy for early-stage NSCLC.

5-Year EMPOWER-Lung 3 Data for Cemiplimab Plus Chemo in Advanced NSCLC

October 13th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss 5-year data for cemiplimab plus chemotherapy in advanced NSCLC.

Managing Immune-Related AEs in NSCLC

October 7th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the management of immune-related adverse effects in advanced NSCLC.

How Cemiplimab Plus Chemo Has Affected First-Line NSCLC Management, Including Squamous Histology

October 7th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the impact of the FDA approval of cemiplimab plus chemotherapy in advanced NSCLC.

Treatment Decision-Making and Sequencing Factors in Advanced Non–Small Cell Lung Cancer

September 29th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss treatment and sequencing considerations in advanced non–small cell lung cancer.

First-line Osimertinib chemo vs osimertinib mono in EGFRm Advanced NSCLC: Flaura2 final overall survival

September 18th 2025

Dr Patel on Remaining Gaps in Biomarker Testing for Early-Stage Resected NSCLC

September 8th 2025

Sandip P. Patel, MD, discusses remaining gaps in biomarker testing and their implications for targeted therapies in early-stage NSCLC.

Dr Patel on Toxicities Associated With Immunotherapy-Based Combinations in NSCLC

July 23rd 2025

Sandip P. Patel, MD, discusses toxicities associated with the use of immunotherapy-based combination regimens in patients with advanced NSCLC.

Looking Ahead: Future Perspectives and Advancements in EGFRm NSCLC

July 16th 2025

Panelists discuss how future developments in EGFR-mutated non–small cell lung cancer (NSCLC) will focus on biomarker-driven patient selection, rational sequencing strategies, and emerging therapies including cellular therapy and treatments for atypical EGFR mutations.

Balancing Safety and Efficacy With ADC-Based Therapies in Advanced EGFRm Non–Small Cell Lung Cancer

July 16th 2025

Panelists discuss how ADC-based therapies like dato-DXd offer superior efficacy compared with traditional chemotherapy options like docetaxel, while requiring careful monitoring for unique toxicities including ILD, stomatitis, and ocular effects.

TROP2 and Dato-DXd in EGFRm Non–Small Cell Lung Cancer: Evolving Biomarkers and Treatment Strategies

July 9th 2025

Panelists discuss how TROP2-targeted ADC dato-DXd represents another promising option with evolving digital pathology biomarker approaches, though practical implementation and patient selection strategies remain challenging.

Exploring the Potential Role of HER3-DXd in Advanced EGFRm Non–Small Cell Lung Cancer

July 9th 2025

Panelists discuss how HER3-directed ADC patritumab deruxtecan shows promise as a later-line therapy with approximately 30% response rates and intracranial activity, though biomarker selection remains elusive and mechanism of CNS penetration unclear.

Treatment Selection and Sequencing Strategies for Advanced EGFRm NSCLC in the Second-Line Setting

July 2nd 2025

Panelists discuss how second-line treatment selection depends heavily on frontline therapy choice, emphasizing the importance of repeat biopsies to identify resistance mechanisms and considering continuation of TKI with added chemotherapy for patients with controlled CNS disease.

Balancing Safety and Efficacy in the Frontline Management of Advanced EGFRm NSCLC

July 2nd 2025

Panelists discuss how balancing safety and efficacy in frontline regimens involves managing distinct toxicity profiles, with FLAURA2 requiring standard chemotherapy monitoring vs MARIPOSA necessitating complex supportive care for EGFR-related skin toxicity and venous thromboembolism prophylaxis.

Treatment Strategies for EGFRm Non–Small Cell Lung Cancer With Visceral or Oligometastatic Disease

June 25th 2025

Panelists discuss how oligometastatic disease treatment requires careful definition of metastatic burden, with liver metastases potentially indicating more aggressive biology and warranting consideration of intensified frontline therapy.

Optimizing Treatment in EGFRm NSCLC With CNS Metastases: Multidisciplinary Management and Monitoring Strategies

June 25th 2025

Panelists discuss how CNS metastases in EGFR-mutated NSCLC require multidisciplinary management with close radiation oncology collaboration, frequent monitoring, and preference for FLAURA2 regimen due to superior intracranial efficacy data.

MARIPOSA in First-Line EGFRm Non–Small Cell Lung Cancer: Patient Selection and Emerging Survival Data

June 18th 2025

Panelists discuss how the MARIPOSA regimen (amivantamab plus lazertinib) shows promising overall survival benefits in first-line treatment, though with increased toxicity concerns including rash, edema, and VTE risk requiring careful patient selection.

FLAURA2 in the Frontline Management of EGFRm NSCLC: Key Considerations for Patient Selection

June 18th 2025

Panelists discuss how FLAURA2 regimen (osimertinib plus chemotherapy) is being incorporated into frontline EGFR-mutated NSCLC treatment, with considerations for escalating to combination therapy based on disease burden, CNS metastases, and patient tolerance factors.